Aquestive Therapeutics, Inc. AQST Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $50.27M+12.9% | $44.55M+2.6% | $43.4M-1.7% | $44.13M-18.6% | $54.23M-5.8% | ||
| $18.37M-1.0% | $18.56M+7.6% | $17.24M+0.4% | $17.17M+0.2% | $17.14M-4.1% | ||
| $31.9M+22.7% | $25.99M-0.6% | $26.16M-3.0% | $26.96M-27.3% | $37.09M-6.5% | ||
| 63.5%+5.1pp | 58.3%-1.9pp | 60.3%-0.8pp | 61.1%-7.3pp | 68.4%-0.5pp | ||
| $16.04M-6.7% | $17.19M-9.1% | $18.91M-3.8% | $19.65M-0.3% | $19.71M-2.8% | ||
| $71.75M-10.1% | $79.85M+26.7% | $63.04M+5.2% | $59.91M+2.3% | $58.56M+16.7% | ||
| $106.16M-8.2% | $115.6M+16.5% | $99.19M+2.5% | $96.73M+1.4% | $95.41M+8.0% | ||
| -$55.89M+21.3% | -$71.05M-27.4% | -$55.79M-6.1% | -$52.6M-27.7% | -$41.18M-33.8% | ||
| -111.2%+48.3pp | -159.5%-30.9pp | -128.6%-9.4pp | -119.2%-43.3pp | -75.9%-22.5pp | ||
| $11.24M+1.1% | $11.12M0.0% | $11.12M0.0% | $11.12M0.0% | $11.12M0.0% | ||
| -$68.91M+17.8% | -$83.78M-21.4% | -$68.99M-6.1% | -$65.06M-19.9% | -$54.25M-22.9% | ||
| -$68.91M+17.8% | -$83.78M-21.5% | -$68.98M-6.1% | -$65.04M-19.9% | -$54.24M-22.9% | ||
| -137.1%+51.0pp | -188.1%-29.1pp | -158.9%-11.6pp | -147.4%-47.4pp | -100%-23.3pp | ||
| -$0.62+21.5% | -$0.79-11.3% | -$0.71-1.4% | -$0.70-18.6% | -$0.59-13.5% | ||
| -$0.62+21.5% | -$0.79-11.3% | -$0.71-1.4% | -$0.70-18.6% | -$0.59-13.5% | ||
| 439.4M+6.6% | 412.3M+5.2% | 392.1M+5.2% | 372.6M+2.3% | 364.2M+6.4% | ||
| 439.4M+6.6% | 412.3M+5.2% | 392.1M+5.2% | 372.6M+2.3% | 364.2M+6.4% | ||
| $5.27M-8.1% | $5.74M+0.9% | $5.69M+1.3% | $5.61M+1.4% | $5.54M+1.4% | ||
| $3.74M-14.4% | $4.37M+13.5% | $3.85M-14.9% | $4.52M+18.3% | $3.82M+11.2% | ||
| $244K+0.4% | $243K+0.4% | $242K+0.8% | $240K+1.3% | $237K+0.4% | ||
| -$68.91M+17.8% | -$83.78M-21.5% | -$68.98M-6.1% | -$65.04M-19.9% | -$54.24M-22.9% | ||
| $50.27M+12.9% | $44.55M+2.6% | $43.4M-1.7% | $44.13M-18.6% | $54.23M-5.8% | ||
| -$55.89M+21.3% | -$71.05M-27.4% | -$55.79M-6.1% | -$52.6M-27.7% | -$41.18M-33.8% | ||
| -$55.37M+21.5% | -$70.5M-27.7% | -$55.23M-6.2% | -$52.02M-28.3% | -$40.53M-34.9% | ||
| -$55.37M+21.5% | -$70.5M-27.7% | -$55.23M-6.2% | -$52.02M-28.3% | -$40.53M-34.9% | ||
| -110.1%+48.1pp | -158.3%-31.0pp | -127.3%-9.4pp | -117.9%-43.1pp | -74.7%-22.5pp | ||
| -$55.89M+21.3% | -$71.05M-27.4% | -$55.79M-6.1% | -$52.6M-27.7% | -$41.18M-33.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Aquestive Therapeutics, Inc.'s revenue?
- Aquestive Therapeutics, Inc. (AQST) generated $50.3M in revenue over the trailing twelve months, down 7.3% year over year.
- Is Aquestive Therapeutics, Inc. profitable?
- Aquestive Therapeutics, Inc. is not currently profitable: it reported a net loss of $68.9M over the trailing twelve months, a -137.1% net margin.
- What are Aquestive Therapeutics, Inc.'s profit margins?
- Gross margin is 63.5% and operating margin is -111.2%, with a -137.1% net margin.
- What is Aquestive Therapeutics, Inc.'s earnings per share?
- Aquestive Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-0.62.
- Where does Aquestive Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Aquestive Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
